Advertisement

Biomimetic Approach to Drug Delivery and Optimization of Nanocarrier Systems

  • E. Turker Baran
  • Rui L. Reis

Keywords

Ethylene Oxide Encapsulation Efficiency Lauryl Ether Biomimetic Approach Ethylene Adipate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kravtzoff R, Colombat PH, Desbois I, Linasser C, Muh JP, Philip T, Blay JY, Gardenbas M, Poumier-Gaschard P, Lamagnere JP, Chassaigne M, Ropars C. Tolerance evaluation of L-asparaginase loaded in red blood cells. Eur J Pharm 1996; 51: 221-5.CrossRefGoogle Scholar
  2. 2.
    Satterfield W, Keeling M. Intraperitoneal administration of carrier erythrocytes in dogs: an improved method for delivery of L-asparaginase 2. Appl Biochem 1990; 12: 331-5.Google Scholar
  3. 3.
    Chambers E, Mitragotri S. Prolonged circulation of large polymeric nanoparticles by non-covalent adsorption on erythrocytes J Control Rel 2004; 100: 111-19.CrossRefGoogle Scholar
  4. 4.
    Feder R, Nehushtai R, Mor A. Affinity driven molecular transfer from erythrocyte membrane to target cells. Peptides 2001; 22: 1683-90.CrossRefPubMedGoogle Scholar
  5. 5.
    Winterhalter M, Hilty C, Bezrukov SM, Nardin C, Meier W, Fournier D. Controlling membrane permeability with bacterial porins: application to encapsulated enzymes. Talanta 2001; 55: 965-71.CrossRefPubMedGoogle Scholar
  6. 6.
    Lee VHL, Sporty JL, Fandy TE. Pharmacogenomics of drug transporters: the next drug delivery challenge. Adv Drug Del Rev 2001; 50: S33-40.CrossRefGoogle Scholar
  7. 7.
    Thomas SLY, Egee S, Lapaix F, Kaestner L, Staines HM, Ellory JC. Malaria parasite plasmodium gallinaceum up-regulates host red blood cell channels. FEBS Lett 2001; 500: 45-51.CrossRefPubMedGoogle Scholar
  8. 8.
    Nagaich S, Khopade AJ, Jain NK. Lipid grafts of egg-box complex: a new supramolecular biovector for 5-fluorouracil delivery. Pharm Acta Helv 1999; 73: 227-36.CrossRefPubMedGoogle Scholar
  9. 9.
    Major M, Prieur E, Tocanne JF, Betbeder D, Sautereau AM. Characterization and phase behaviour of phospholipid bilayers adsorbed on spherical polysaccharidic nanoparticles. Biochim Biophys Acta 1997; 1327: 32-40.CrossRefPubMedGoogle Scholar
  10. 10.
    Hoegen PV. Synthetic biomimetic supramolecular biovector (SMBV) particles for nasal vaccine delivery. Adv Drug Del Rev 2001; 51: 113-25.CrossRefGoogle Scholar
  11. 11.
    Kiser PF, Wilson G, Needham D. Lipid-coated microgels for the triggered release of doxorubicin. J Control Rel 2000; 68: 9-22.CrossRefGoogle Scholar
  12. 12.
    Rensen PCN, de Vrueth RLA, Kuiper J, Bijsterbosch MK, Biessen EAL, van Berkel TJC. Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Del Rev 2001; 47: 251-76.CrossRefGoogle Scholar
  13. 13.
    Chu ACY, Tsabg SY, Lo EHK, Funk KP. Low density lipoprotein as a targeted carrier for doxorubicin in nude mice bearing human hepatoma HepG2 cells. Life Sci 2001; 70: 591-601.CrossRefPubMedGoogle Scholar
  14. 14.
    Utreja S, Khopade AJ, Jain NK. Lipoprotein-mimicking biovectorized systems for methotrexate delivery. Pharma Acta Helvetiae 1999; 73: 275-79.CrossRefGoogle Scholar
  15. 15.
    Song C, Labhasetwar V, Murphy H, Qu X, Humphrey WR, Shebuski RJ, Levi RJ. Formulations and characterisation of biodegradable nanoparticles for intravascular local drug delivery. J Control Rel 1997; 43: 197-212.CrossRefGoogle Scholar
  16. 16.
    Gibaud S, Rousseau C, Weingarter C, Favier R, Douay L, Andreux JP, Couvreur P. Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte-colony stimulating factor (G-CSF). J Control Rel 1998; 52: 131-39.CrossRefGoogle Scholar
  17. 17.
    Lemoine D, Preat V. Poymeric nanoparticles as the delivery system for influenza virus gycoproteins. J Control Rel 1998; 54: 15-27.CrossRefGoogle Scholar
  18. 18.
    Lin W, Garnett MC, Davies MC, Bignotti F, Fernutti P, Davis SS, Illum L. Preparation of surface modified albumin nanospheres. Biomaterials 1997; 18: 559-65.CrossRefPubMedGoogle Scholar
  19. 19.
    Jeong Y, Cheon J, Kim S, Nah J, Lee Y, Sung Y, Akaike T, Cho C. Clonazepam release from core-shell type nanoparticles in vitro. J Control Rel 1998; 51: 169-78.CrossRefGoogle Scholar
  20. 20.
    Aboubakar M, Puisieux F, Couvreur P, and Vauthier C. Physico-chemical charac-terization of insulin-loaded poly(isobutylcyanoacrylates) nanocapsules obtained by interfacial polymerization. Int J Pharm 1999; 183: 63-66.CrossRefPubMedGoogle Scholar
  21. 21.
    Sendil D, Gursel I, Wise DL, Hasirci V. Antibiotic release from biodegradable PHBV microparticles. J Control Rel 1999; 59: 207-17.CrossRefGoogle Scholar
  22. 22.
    Pouton CW, Akhtar S. Biosynthetic polyhydroxyalkonates and their potential in drug delivery. Adv Drug Deliver Rev 1996; 18: 133-62.CrossRefGoogle Scholar
  23. 23.
    Gangrade N, Price JC. Poly(hydroxybutyrate-hydroxyvalerate) microspheres containing progesterone: preparation, morphology and release properties. J Microencapsul 1991; 8: 185-202.CrossRefPubMedGoogle Scholar
  24. 24.
    Embleton JK, Tighe BJ. Polymers for biodegradable medical devices. Encapsulation studies: control of poly-hydroxybutyrate-hydroxyvalerate microcapsules porosity via polycaprolactone blending. J Microencapsul 1993; 10: 341-52.CrossRefPubMedGoogle Scholar
  25. 25.
    Conway BR, Eyles JE, Alpar HO. A comparative study on the immune responses to antigens in PLA and PHB microspheres. J Control Rel 1997; 49: 1-9.CrossRefGoogle Scholar
  26. 26.
    Atkins TW. Fabrication of microcapsules using poly(ethylene adipate) and a blend of poly(ethylene adipate) with poly(hydroxybutyrate-hydroxyvalerate). Incorporation and release of bovine serum albumin. Biomaterials 1997; 18: 173-80.CrossRefPubMedGoogle Scholar
  27. 27.
    Sendil D. 1997; Antibiotic release from biodegradable microbial polyesters. M.S. thesis, Middle East Technical University, Ankara, Turkey.Google Scholar
  28. 28.
    Gaspar MM, Blanco D, Cruz ME, Alonso MJ. Formulation of L-asparaginase-loaded poly(lactide-co-glycolide) nanoparticles: influence of polymer properties on enzyme loading, activity and in vitro release. J Control Rel 1998; 52: 53-62.CrossRefGoogle Scholar
  29. 29.
    Calvo P, Remunan-Lopez, C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 1997; 63: 125-32.CrossRefGoogle Scholar
  30. 30.
    Baran ET, Ozer N, Hasirci V. Nanoencapsulation of asparaginase into Poly(hydroxy-butyrate-hydroxy-valerate) nanocapsules. J Mater Sci: Mater Med 2002; 12: 1113-21.CrossRefGoogle Scholar
  31. 31.
    Ranney DF. Biomimetic transport and rational drug delivery. Biochem Pharma 2000; 59: 105-14.CrossRefGoogle Scholar
  32. 32.
    Kim ES, Lu C, Khuri FR, Tonda M, Glisson BS, Liu D, Jung M, Hong WK. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 2001; 34: 427-32.CrossRefPubMedGoogle Scholar
  33. 33.
    Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K. Long circulating poly(ethylene glycol)-poly(DL-lactide) block copolymers micelles with modulated surface charge. J Control Rel 2001; 77: 27-38.CrossRefGoogle Scholar
  34. 34.
    Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Muller RH. Stealth’ corona-core nanoparticles surface polymodified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloid Surf B Biointerf 2000; 18: 301-13.CrossRefGoogle Scholar
  35. 35.
    Li YP, Pei YY, Zhang XY, Gu ZH, Zhou ZH, Yuan WF, Zhou JJ, Zhu JH, Gao XJ. PEGYlated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Rel 2001; 71: 203-11.CrossRefGoogle Scholar
  36. 36.
    Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Del Rev 2001; 47: 113-31.CrossRefGoogle Scholar
  37. 37.
    Calvo P, Gouritin B, Brigger I, Lasmezas C, Deslys J, Williams A, Andreux JP, Dormont D, Couvreur P. PEGy lated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. J Neurosci Meth 2001; 111: 151-5.CrossRefGoogle Scholar
  38. 38.
    Brigger I, Chaminade P, Marsaud V, Appel M, Besnard M, Gurny R, Renoir M, Couvreur P. Tamoxifen encapsulation within polyethylene glycol-coated nanospheres: a new antiestrogen formulation. Int J Pharm 2001; 214: 37-42.CrossRefPubMedGoogle Scholar
  39. 39.
    Mosqueira VCF, Legrand P, Gulik A, Bourdon O, Gref R, Labarre D, Barratt G. Relationship between complement activation, cellular uptake and surface physico-chemical aspects of novel PEG-modified nanocapsules. Biomaterials 2001; 22: 2967-79.CrossRefPubMedGoogle Scholar
  40. 40.
    Redhead HM, Davis SS, Illum L. Drug delivery in poly(lactide-coglycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterization and in vivo evaluation. J Control Rel 2001; 70: 353-63.CrossRefGoogle Scholar
  41. 41.
    Stolnik S, Daudali B, Arien A, Whetstone J, Heald CRM, Garnett C, Davis SS, Illum L. The effect of surface coverage and conformation of poly(ethylene oxide) (PEO) chains of  poloxamer407 on the biological fate of model colloidal drug carriers. BBA Biomembranes 2001; 1514: 261-79.CrossRefPubMedGoogle Scholar
  42. 42.
    Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J Control Rel 1997; 49: 81-7.CrossRefGoogle Scholar
  43. 43.
    Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE, Turowski B, Zanella FE, Kreuter J. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol Lett 2002; 126: 131-41.CrossRefPubMedGoogle Scholar
  44. 44.
    Photos PJ, Bacakova L, Discher B, Bates FS, Discher DE. Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Rel 2003; 90: 323-34.CrossRefGoogle Scholar
  45. 45.
    Moghimi SM, Hunter AC. Poloxamers and polyamines in nanoparticle engineering and experimental medicine. TIBTECH 2000; 18: 412-20.Google Scholar
  46. 46.
    Zambaux MF, Bonneaux F, Gref R, Dellacherie E, Vigneron C. Protein C-loaded monomethoxypoly (ethylene oxide)-poly(lactic acid) nanoparticles. J Pharm 2001; 212: 1-9.Google Scholar
  47. 47.
    Maiti S, Jayachandran KN, Chatterji PR. Probing the association behaviour of poly(ethyleneglycol) based amphiphilic comb-like polymer. Polymer 2001; 42: 7801-8.CrossRefGoogle Scholar

Copyright information

© Springer 2006

Authors and Affiliations

  • E. Turker Baran
    • 1
  • Rui L. Reis
    • 2
  1. 1.3B's Research Group-Biomaterials, Biodegradables and BiomimeticsUniversity of MinhoPortugal
  2. 2.3B's Research Group-Biomaterials, Biodegradables and BiomimeticsUniversity of MinhoPortugal

Personalised recommendations